UOC
SYRS

UBS O'Connor’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

UBS O'Connor’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-359,305
Closed -$773K – 600
2024
Q3 		$773K Buy
359,305
+81,202
+29% +$292K 0.02% 304
2024
Q2 		$1.44M Buy
278,103
+103,103
+59% +$542K 0.04% 244
2024
Q1 		$936K Buy
175,000
+45,000
+35% +$311K 0.03% 282
2023
Q4 		$1.01M Buy
+130,000
New +$445K 0.03% 269

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

UBS O'Connor's SYRS Position: Q4 2024 in Review

UBS O'Connor sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2024, closing a stake of 359,305 shares — an estimated $773K sold.

UBS O'Connor first reported a position in SYRS in Q4 2023 and held it in 4 quarters. The position peaked at $1.44M in Q2 2024. 44 funds tracked by Wall St. Rank hold SYRS as of Q4 2024.

  • UBS O'Connor reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • UBS O'Connor sold 359,305 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $773K.
  • UBS O'Connor first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2023 and held it in 4 quarters.
  • UBS O'Connor's Syros Pharmaceuticals, Inc. Common Stock position peaked at $1.44M in Q2 2024.
  • 44 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on UBS O'Connor's 13F filing for Q4 2024, filed 14 Feb 2025.